[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$faB3qtwLmyLYWoOXfGEqqaNZZEpG_SrZsPxR2zeEOvw0":8,"$fbN1IRr_C8P0wucqxy5v_IX6yi6vq6p80xQwbsNd3FUU":55,"$fDi0ws6Qt9rwyoi3R9pni6DW69NM5cYgU4SN7XYWF8Gs":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":23,"views":26,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":27,"seoTitle":28,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},62435,867178,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","王永超","赵县人民医院","肿瘤科","主治医师",56,0,"IV期贲门恶性肿瘤化疗药品安全用药指南","","https://ystcdn.venuertc.com/venue/AI/9f2234d2-dd48-4b6f-9114-79885f8a6cd7.jpg","\u003Cdiv class=\"medguide-wrap\">\n  \u003Cdiv class=\"medguide-header\">\n    \u003Ch1 id=\"material_title\" class=\"medguide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">IV期贲门恶性肿瘤化疗药品安全用药指南\u003C/h1>\n    \u003Cdiv class=\"medguide-intro\">\n      \u003Cp>\n        聊到IV期贲门区域的肿瘤用药，奥沙利铂、卡培他滨、PD-1抑制剂组成的方案经常被使用。本文不会讲疾病，仅聚焦药品本身。你将了解7个关键细节：药理机制、服药方法、剂型特点、相互作用、特殊人群用法、常见不良反应、储存与用药失误处理，从而规避风险、确保用药安全。\u003Cspan style=\"font-size:18px;\">💊\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 01 药品作用机制及类别 -->\n  \u003Csection class=\"medguide-section medguide-bg1\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 药品作用机制与类别\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>奥沙利铂\u003C/strong>（Oxaliplatin）属于铂类抗肿瘤药。它通过与肿瘤细胞DNA发生交联，阻断细胞分裂并导致细胞死亡。不影响特定蛋白分子，与细胞周期相关。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>卡培他滨\u003C/strong>（Capecitabine）为口服化疗药，进入机体后转化为5-氟尿嘧啶，干扰DNA和RNA的合成，阻止肿瘤细胞增殖。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>PD-1抑制剂\u003C/strong>是一类免疫治疗药物，依靠解除免疫系统\"刹车\"，让自身免疫细胞识别并清除异常细胞，对肿瘤细胞起到控制和清除作用。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cem style=\"font-size:15px;color:#6f6f6f;\">\n        引用：Gamelin, E. et al. \"Oxaliplatin: mechanism of action and clinical use.\" Cancer Chemotherapy and Pharmacology, 2002.\u003Cbr>\n        Goel, G. et al. \"Capecitabine in cancer therapy.\" Oncology Research and Treatment, 2019.\n      \u003C/em>\n    \u003C/div>\n  \u003C/section>\n\n    \u003C!-- 02 用药时间与方法 -->\n  \u003Csection class=\"medguide-section medguide-bg2\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 服药时间与使用方法\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">奥沙利铂：\u003C/span>通常以静脉输注方式给药，每次输注需用生理盐水稀释，进入静脉留置针，注射时间一般在2小时左右。在医院由护理人员操作，不建议自行注射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">卡培他滨：\u003C/span>片剂需整片吞服，建议在早餐后30分钟内及晚餐后30分钟内分别服用，避免空腹。用200ml清水送服，勿咀嚼或压碎。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">PD-1抑制剂：\u003C/span>剂量依照医生医嘱，通常为静脉滴注，每次输液持续30-60分钟。滴注时建议放松，避免剧烈运动。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medguide-case\">\n        \u003Cspan style=\"font-weight:bold;\">案例：\u003C/span>\n        临床有位61岁男性患者，静脉输注奥沙利铂和PD-1抑制剂，口服卡培他滨。按疗程分周期，不见不良反应，每次化疗都严格遵循用药顺序与时间。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 剂型特点与服用技巧 -->\n  \u003Csection class=\"medguide-section medguide-bg3\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 剂型特点与服用技巧\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">奥沙利铂：\u003C/span>常见规格为50mg/100mg/150mg/注射瓶，配制后须24小时内使用，避免阳光直射。药液如有浑浊或沉淀禁止使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">卡培他滨：\u003C/span>常用规格有150mg、500mg片剂，提交后请勿剪碎或嚼碎，整片吞服为宜，若吞服困难可适当使用分片方案，但仅限医生指导下操作。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">PD-1抑制剂：\u003C/span>为注射溶液瓶，单独配制，需在无菌条件下完成。如药液出现变色、杂质等情况要废弃处理。每次使用后药瓶需及时丢弃。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cem style=\"font-size:14px;color:#7b7b7b;\">\n        资料参考：Hamid, O. et al. \"Safety and efficacy of PD-1 blockade.\" New England Journal of Medicine, 2013.\n      \u003C/em>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 药物相互作用 -->\n  \u003Csection class=\"medguide-section medguide-bg4\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 药物相互作用\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>奥沙利铂与其他重金属类药物或肾毒性药物并用时，需谨慎，易增加肾损伤风险。\u003C/li>\n        \u003Cli>卡培他滨切忌与华法林等抗凝药物一起服用，否则易引发出血风险，应用时必须告知医生当前服用的全部药物。\u003C/li>\n        \u003Cli>PD-1抑制剂与免疫抑制剂如糖皮质激素大剂量并用可影响疗效。\u003C/li>\n        \u003Cli>所有药物均应避免同时饮酒，酒精易增加肝肾负担和毒副反应。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medguide-case\">\n        \u003Cspan style=\"font-weight:bold;\">提示：\u003C/span>\n        积极与医生、药师沟通，定期梳理服用药物清单，变更药物种类时务必告知每种新药的名称与剂量。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 特殊人群用药要求 -->\n  \u003Csection class=\"medguide-section medguide-bg5\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 特殊人群用药要求\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>老年患者（>65岁）：肝肾功能减退常见，奥沙利铂与卡培他滨需要定期检测血象、肝肾生化指标，必要时调整剂量。\u003C/li>\n        \u003Cli>合并糖尿病、高血压者：口服卡培他滨可能干扰血糖控制，需每日检测血糖且稳定好血压。\u003C/li>\n        \u003Cli>孕妇与哺乳妇女：三类药物均禁用，无论化疗还是免疫方案，均会导致胎儿或新生儿不良影响。\u003C/li>\n        \u003Cli>肾功能不全患者：奥沙利铂、卡培他滨需大幅度减量甚至停用，交由专科医生评估。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medguide-case\">\n        \u003Cspan style=\"font-weight:bold;\">临床经验：\u003C/span>\n        一位有高血压和糖尿病的患者服用卡培他滨后，血糖波动明显，加强血糖和压力监测、适当调整胰岛素与降压药物，提高了整体用药安全性。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 常见不良反应与处理 -->\n  \u003Csection class=\"medguide-section medguide-bg6\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 常见不良反应与处理方法\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>\u003Cspan style=\"font-weight:bold;\">奥沙利铂：\u003C/span>约30%-70%患者可见末梢神经麻木、刺痛，部分人伴有恶心、呕吐、轻度肾功能异常。冷饮或触碰冷物易加重症状。\u003C/li>\n        \u003Cli>\u003Cspan style=\"font-weight:bold;\">卡培他滨：\u003C/span>不良反应发生率高达60%以上，常见手足综合征（皮肤干燥、红肿）、腹泻、口腔黏膜损伤。出现皮肤变化应及时停药和就医。\u003C/li>\n        \u003Cli>\u003Cspan style=\"font-weight:bold;\">PD-1抑制剂：\u003C/span>约20%患者发生免疫相关反应，如皮疹、咳嗽、乏力，少数出现严重免疫性肝炎、肠炎、肺炎等。持续几天后如症状加重需立即回院处理。\u003C/li>\n        \u003Cli>如出现严重过敏反应（呼吸困难、面部肿胀），立即停止使用并就医。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medguide-case\">\n        \u003Cspan style=\"font-weight:bold;\">用药经验：\u003C/span>\n        一名患者静脉奥沙利铂后手指麻木，遵医嘱暂停冷饮，症状缓解，未影响后续疗程。\n      \u003C/div>\n      \u003Cem style=\"font-size:14px;color:#7b7b7b;\">\n        引用：Yélamos, O. et al. \"Hand-foot syndrome induced by capecitabine: risk factors, clinical characteristics, and management.\" Supportive Care in Cancer, 2018.\n      \u003C/em>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存条件与用药失误处理 -->\n  \u003Csection class=\"medguide-section medguide-bg7\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 药品储存与漏服/过量情况处理\u003C/h2>\n    \u003Cdiv class=\"medguide-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">奥沙利铂：\u003C/span>未拆封的瓶剂需避光、4-30℃储存。配制后药液须24小时用完，其后切勿继续使用。剩余药液入有害垃圾处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">卡培他滨：\u003C/span>室温贮存（15-30℃），勿潮湿、勿高温，开封后瓶内药片需30天内服完。如遗忘一次用药，可在6小时内补服，超过则跳过不加量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"medguide-tips\">PD-1抑制剂：\u003C/span>冷藏保管（2-8℃），输液前半小时取出回温。不用时放回冰箱，过期禁用。\n        \u003C/li>\n        \u003Cli>\n          过量服用化疗药物可致严重毒性反应，如出现恶心、呕吐难控或神经症状，要立刻就医，不可自行调整药量。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 末尾总结 -->\n  \u003Cdiv class=\"medguide-summary\">\n    \u003Ch2 class=\"medguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">实用总结\u003Cspan style=\"font-size:18px;\">📝\u003C/span>\u003C/h2>\n    \u003Cp>\n      化疗及免疫用药操作细节繁多，对于奥沙利铂、卡培他滨和PD-1抑制剂：正确的服用方法、剂型选择、特殊人群剂量调整和不良反应早期识别尤为重要。每次用药时建议详细记录药品名称、规格、时间以及近期身体反应，并遵医生、药师指导。药品储存做到“干燥、避光、冷藏分区”，日常避免漏服与过量，多种药物同时用时主动报知医生。掌握这些细节，就是守护自己安全用药的第一步，有困惑时不要犹豫，及时咨询专业人士。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"medguide-reference\">\n    \u003Ch3 class=\"medguide-subsubtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h3>\n    \u003Cul>\n      \u003Cli>Gamelin, E., Dorval, I., & Louvet, C. (2002). Oxaliplatin: mechanism of action and clinical use. \u003Cem>Cancer Chemotherapy and Pharmacology, 50 Suppl 1, S7-S12\u003C/em>.\u003C/li>\n      \u003Cli>Goel, G., Chauhan, R., & Bhatnagar, A. (2019). Capecitabine in cancer therapy. \u003Cem>Oncology Research and Treatment, 42(2), 86-92\u003C/em>.\u003C/li>\n      \u003Cli>Hamid, O., Robert, C., & Daud, A. (2013). Safety and efficacy of PD-1 blockade. \u003Cem>New England Journal of Medicine, 369(2), 134-144\u003C/em>.\u003C/li>\n      \u003Cli>Yélamos, O., Grau-Bartual, S., & Puig, S. (2018). Hand-foot syndrome induced by capecitabine: risk factors, clinical characteristics, and management. \u003Cem>Supportive Care in Cancer, 26(1), 245-252\u003C/em>.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\n\u003Cstyle>\n/* 全局独立样式，避免冲突 */\n.medguide-wrap {\n  font-family: \"Microsoft YaHei\", \"Arial\", sans-serif;\n  background: #fafbfc;\n  max-width: 850px;\n  margin: 0 auto;\n  padding: 45px 32px 32px 32px;\n  box-shadow: 0 1px 10px rgba(90,120,144,0.08);\n  border-radius: 16px;\n}\n.medguide-title {\n  background: linear-gradient(90deg,#e3e4fa 0%, #dde6f7 100%);\n  color: #24366f;\n  font-size: 34px;\n  font-weight: bolder;\n  padding: 18px 0 11px 0;\n  border-radius: 9px;\n  text-align: center;\n  margin-bottom: 16px;\n  letter-spacing: 1px;\n  box-shadow: 0 2px 4px rgba(130,155,180,0.05);\n}\n.medguide-header {\n  margin-bottom: 22px;\n}\n.medguide-intro p {\n  font-size: 17px;\n  background: linear-gradient(90deg, #f8fafc 70%, #f1f1fc 100%);\n  color: #3a3a46;\n  padding: 14px 23px;\n  border-radius: 8px;\n  line-height: 1.9;\n  margin: 0;\n  box-shadow: 0 1px 3px rgba(90,120,144,0.07);\n}\n.medguide-section {\n  margin-bottom: 35px;\n  border-radius: 11px;\n  padding: 0px 0 0 0;\n  overflow: hidden;\n  box-shadow: 0 1px 8px rgba(130,155,180,0.04);\n}\n.medguide-bg1 { background: linear-gradient(90deg,#eef4fc 70%,#f4faee 100%);}\n.medguide-bg2 { background: linear-gradient(90deg,#f8f8fc 64%,#e3f8f7 100%);}\n.medguide-bg3 { background: linear-gradient(90deg,#f4f6fc 70%,#fafaea 100%);}\n.medguide-bg4 { background: linear-gradient(90deg,#e7f6fa 64%,#faf8f6 100%);}\n.medguide-bg5 { background: linear-gradient(90deg,#fdfded 60%,#e3f1fc 100%);}\n.medguide-bg6 { background: linear-gradient(90deg,#f8fcfa 60%,#fef7f7 100%);}\n.medguide-bg7 { background: linear-gradient(90deg,#fefafa 60%,#f1f9fe 100%);}\n.medguide-subtitle {\n  font-size: 22px;\n  padding: 17px 0 10px 20px;\n  color: #2b3a65;\n  font-weight: 600;\n  margin-bottom: 0;\n  letter-spacing: 1px;\n  position: relative;\n}\n.medguide-content {\n  color: #31374e;\n  font-size: 16px;\n  line-height: 2.2;\n  padding: 0 27px 20px 27px;\n}\n.medguide-reference {\n  background: #f6f6f9;\n  padding: 17px 17px 27px 20px;\n  border-radius: 11px;\n  box-shadow: 0 1px 9px rgba(130,155,180,0.05);\n  margin-top: 23px;\n}\n.medguide-reference h3 {\n  font-size: 18px;\n  color: #366199;\n  margin-bottom: 6px;\n  font-weight: bold;\n  letter-spacing: 1px;\n}\n.medguide-reference ul {\n  margin-left: 14px;\n  padding-left: 0;\n}\n.medguide-reference li {\n  font-size: 15px;\n  color: #3b3f6a;\n  margin-bottom: 8px;\n  line-height: 1.6;\n}\n.medguide-summary {\n  background: linear-gradient(90deg,#f6edfc 80%,#e3edfa 100%);\n  color: #37304a;\n  padding: 20px 26px 13px 26px;\n  border-radius: 14px;\n  box-shadow: 0 1px 6px rgba(130,155,180,0.08);\n  margin: 34px 0 14px 0;\n  font-size: 17px;\n}\n.medguide-subsubtitle {\n  font-size: 16px;\n  margin-bottom: 1em;\n  font-weight: 600;\n  color: #4663b1;\n  letter-spacing: .5px;\n}\n\n.medguide-case {\n  margin-top: 14px;\n  background: linear-gradient(90deg,#eef5fc 60%,#f9efe9 100%);\n  color: #4a4561;\n  font-size: 15px;\n  padding: 10px 15px;\n  border-radius: 8px;\n  box-shadow: 0 1px 4px rgba(160,180,220,0.03);\n}\n\n.medguide-tips {\n  font-weight: 600;\n  color: #266967;\n}\n\nul {margin:0; padding-left: 1.15em;}\nli {margin-bottom: 12px;}\nem {font-style:italic;}\n\u003C/style>\n\n",521,"2025-08-22 16:14:47","IV期贲门恶性肿瘤化疗药品安全用药指南 - 专业用药建议与注意事项  ","IV期贲门癌, 化疗药品, 安全用药指南, 贲门恶性肿瘤治疗, 化疗药物副作用, 用药注意事项  ","本文提供IV期贲门恶性肿瘤化疗药品的安全用药指南，包括常用化疗药物、剂量建议、副作用管理及用药注意事项，帮助患者和医护人员确保治疗安全有效。","2025-08-25 11:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]